Proxy fight at Echo Therapeutics


A proxy fight over the election of a director looms at Echo Therapeutics' (ECTE +2.4%) June 19 shareholders meeting. The company favors current director and interim CEO Robert F. Doman while institutional shareholder Platinum Management favors Shepard M. Goldberg. As is usually the case, the core of the dispute pertains to the strategic direction of the company.

Comments (4)
  • Wally Cat
    , contributor
    Comments (18) | Send Message
     
    All I know is whomever can raise their darn stock price is who I want. I'm very disappointed that I'm invested in this company right now.
    10 Jun 2014, 01:54 PM Reply Like
  • mazlat10
    , contributor
    Comments (211) | Send Message
     
    Doman takes 450k from the company's money to protect his place as a board member............ never seen something like this..........
    10 Jun 2014, 02:49 PM Reply Like
  • peterarnette
    , contributor
    Comment (1) | Send Message
     
    The money wasted in the multiple proxy mailings and follow up phone calls shows that neither side cares about the stockholders.
    10 Jun 2014, 03:32 PM Reply Like
  • mazlat10
    , contributor
    Comments (211) | Send Message
     
    Platinum spends its OWN money to fight. Doman spends OUR money to fight....................
    11 Jun 2014, 10:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs